APA (7th ed.) Citation

MA, V., R, B., P, d. T., D, B., L, S., P, G., . . . Pétour, P. (2010). Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients. Journal of Antimicrobial Chemotherapy (JAC), 65(3), 556. https://doi.org/10.1093/jac/dkp462

Chicago Style (17th ed.) Citation

MA, Valantin, et al. "Switching the Nucleoside Reverse Transcriptase Inhibitor Backbone to Tenofovir Disoproxil Fumarate + Emtricitabine Promptly Improves Triglycerides and Low-density Lipoprotein Cholesterol in Dyslipidaemic Patients." Journal of Antimicrobial Chemotherapy (JAC) 65, no. 3 (2010): 556. https://doi.org/10.1093/jac/dkp462.

MLA (9th ed.) Citation

MA, Valantin, et al. "Switching the Nucleoside Reverse Transcriptase Inhibitor Backbone to Tenofovir Disoproxil Fumarate + Emtricitabine Promptly Improves Triglycerides and Low-density Lipoprotein Cholesterol in Dyslipidaemic Patients." Journal of Antimicrobial Chemotherapy (JAC), vol. 65, no. 3, 2010, p. 556, https://doi.org/10.1093/jac/dkp462.